Evotec Investor Presentation Deck
evotec
Targeted revenue development
(in € m)
CAGR
~15%
PAGE 31
501
2020
618
2021
Clear strategy in place
Growth and investment strategy overview - Action Plan 2025
2022 (e)
2023 (e) 2024 (e)
>1,000
2025 (e)
Revenue
composition
2020
EVT Execute
Just - Evotec
Biologics¹)
EVT Innovate
Goal revenue
composition
¹) Just - Evotec Biologics reports under the EVT Execute segment
EVT Execute
Just - Evotec
Biologics¹)
EVT Innovate
~20%
~10%
>25%
≥2x
>30%
~70%
>40%
●
Composition of
revenue mix expected
to change over time
while ALL fields
continue to grow
Shifting to even more
favourable revenue
mix expected to drive
increased profitability
• Just Evotec Bio-
logics growth driven
by use of J.PODⓇ
manufacturing
• First small royalties
from pipeline assets
expected in 2025View entire presentation